Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world check on new CMV drugs in transplant patients

NCT ID NCT04690933

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 400 stem cell transplant recipients to see how well anti-CMV medications work in everyday hospital care. Researchers tracked infections, drug resistance, and side effects. The goal was to gather real-life data to improve treatment guidelines for these high-risk patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Started

Sep 2020

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Candidate (adult) for an allograft of hematopoietic stem cells for which a decision of transplant is made and willing to participate in the cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : • Candidate (adult) for an allograft of hematopoietic stem cells for which a decision of transplant is made and willing to participate in the cohort. Exclusion Criteria : * CMV-seronegative patient receiving a negative CMV donor graft ; * Patient having signed the consent but not grafted ; * Patient included in a clinical study on an anti-CMV molecule ; * Non-insured social patient ;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiviral drug resistance are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiviral drug resistance Antivirals Cytomegalovirus infections Hematopoietic stem cell transplantation

Contacts and locations

Locations

  • APHP

    Paris, France

  • CHU

    Amiens, France

  • CHU

    Angers, France

  • CHU

    Besançon, France

  • CHU

    Bordeaux, France

  • CHU

    Caen, France

  • CHU

    Clermont-Ferrand, France

  • CHU

    Grenoble, France

  • CHU

    Montpellier, France

  • CHU

    Nancy, France

  • CHU

    Poitiers, France

  • CHU

    Rouen, France

  • CHU

    Saint-Etienne, France

  • CHU

    Strasbourg, France

  • CHU de LIMOGES

    Limoges, Limoges, 87045, France

  • HCL

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.